Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

Remedy Meds is an online consumer health and pharmacy platform that provides access to compounded glucagon-like peptide-one ...

Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

Weight loss surgery and medications have both been successful in helping patients shed weight, but surgery has been found to be more effective in a recent study, with combination therapy being the ...

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage of these medications.

Russell Crowe's beautiful mind is focused on his health. The Oscar winner said he dropped from 126 kg (277 lbs.) to 100.9 kg (222 lbs.) since wrapping filming on the historical drama Nuremberg over a ...

During an announcement about lowering prices for weight-loss medications, Donald Trump referenced his communications director, Steve Cheung, saying he takes Ozempic. The comment came as Trump promoted ...

The Trump administration announced a deal with Eli Lilly, Novo Nordisk in a bid to lower weight-loss drug prices. Feds Suspend 7,000 Truckers Over New Rule A Massive New Study Says This Is What ...

(RTTNews) - Lineage, Inc. (LINE), a temperature-controlled warehouse REIT, on Wednesday, reported its net loss narrowed in the third quarter compared with the previous year. For the third quarter, net ...

(RTTNews) - Lucid Group (LCID), an electric-vehicle manufacturer, on Wednesday reported a loss in the third quarter of 2025. LCID reported a net loss of $1.03 billion or $3.31 per share, compared to a ...

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...